Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT05737706
Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
- NCT05737706 ↗
- Terminated
- Mirati Therapeutics Inc.
- Focused
We haven't built an HCP commentary report on NCT05737706 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT05737706 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
- Phase
- Phase 1
- Status
- Terminated
- Conditions
- Solid Tumor; Advanced Solid Tumor; Non-small Cell Lung Cancer; Colo-rectal Cancer; Pancreatic Adenocarcinoma
- Interventions
- MRTX1133
- Arms
- Phase 1/1B · Experimental
- Phase 2 · Experimental
- Enrollment
- 63
- Primary outcomes
- Phase 1: Number of Patients who Experience Dose-Limiting Toxicity
- Phase 1/1b: Number of patients who experience a treatment-related adverse event
- Phase 2: Objective response rate (ORR)
- Phase 2: Duration of response (DOR)
- Phase 2: Progression free survival (PFS)
- Phase 2: Overall survival (OS)
- Sponsor
- Mirati Therapeutics Inc.
- Start
- Mar 6, 2023
- Primary completion
- Mar 10, 2025
- Results posted
- No
- Registry record
- NCT05737706 · updated Apr 6, 2025